Group items tagged

Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease.\nEvatt ML, Delong MR, Khazai N, Rosen A, Triche S, Tangpricha V.\nArch Neurol. 2008 Oct;65(10):1348-52.\nPMID: 18852350

Gateway to Tampa Bay area news, weather, radar, sports, traffic, and more. From WTVT-TV/DT FOX 13, the most powerful name in local news.

A multi-institutional team of researchers led by Emory University has defined for the first time how metal ions bind to amyloid fibrils in the brain in a way that appears toxic to neurons. Amyloid fibrils are linked to the development of neurodegenerative

Newmark HL, Newmark J. Vitamin D and Parkinson's disease--a hypothesis. Mov Disord. 2007 Mar 15;22(4):461-8. PMID: 17230473 [PubMed - indexed for MEDLINE]

Coenzyme Q10. Bonakdar RA, Guarneri E. Am Fam Physician. 2005 Sep 15;72(6):1065-70. Review. PMID: 16190504 Coenzyme Q10 is a vitamin-like substance used in the treatment of a variety of disorders primarily related to suboptimal cellular energy metabolism and oxidative injury. Studies supporting the efficacy of coenzyme Q10 appear most promising for neurodegenerative disorders such as Parkinson's disease and certain encephalomyopathies for which coenzyme Q10 has gained orphan drug status. Results in other areas of research, including treatment of congestive heart failure and diabetes, appear to be contradictory or need further clarification before proceeding with recommendations. Coenzyme Q10 appears to be a safe supplement with minimal side effects and low drug interaction potential.

"Results of the first placebo-controlled, multicenter clinical trial of the compound coenzyme Q10 suggest that it can slow disease progression in patients with early-stage Parkinson's disease (PD). While the results must be confirmed in a larger study, they provide hope that this compound may ultimately provide a new way of treating PD. The phase II study, led by Clifford Shults, M.D., of the University of California, San Diego (UCSD) School of Medicine, looked at a total of 80 PD patients at 10 centers across the country to determine if coenzyme Q10 is safe and if it can slow the rate of functional decline. The study was funded by the National Institute of Neurological Disorders and Stroke (NINDS) and appears in the October 15, 2002, issue of the Archives of Neurology"